To this end, a complex DDS was designed to deliver IDO1 inhibitor (NLG919) into tumour sites, and the intratumour kynurenine concentration was dramatically reduced, with increased proportions of CD8+ T cells, Tem and DCs.176. The gene discussed is CD8A; the disease is neoplasm.